Clinical-imaging metrics for the diagnosis of prostate cancer in PI-RADS 3 lesions

被引:0
|
作者
Kang, Zhen [1 ,6 ]
Margolis, Daniel J. [2 ]
Tian, Ye [3 ]
Li, Qiubai [4 ]
Wang, Shaogang [5 ]
Wang, Liang [6 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Radiol, Wuhan, Peoples R China
[2] New York Presbyterian, Weill Cornell Med, Dept Radiol, New York, NY USA
[3] Capital Med Univ, Affiliated Beijing Friendship Hosp, Dept Urol, Beijing, Peoples R China
[4] Univ Hosp Cleveland Med Ctr, Dept Radiol, Cleveland, OH USA
[5] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan, Peoples R China
[6] Capital Med Univ, Beijing Friendship Hosp, Dept Radiol, Beijing, Peoples R China
关键词
Prostate cancer; Clinically significant prostate cancer; PI-RADS; 3; Coefficient of variation; Apparent diffusion coefficient; APPARENT DIFFUSION-COEFFICIENT; DENSITY; GRADE; MRI;
D O I
10.1016/j.urolonc.2024.06.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To explore the feasibility and efficacy of clinical-imaging metrics in the diagnosis of prostate cancer (PCa) and clinically significant prostate cancer (csPCa) in prostate imaging-reporting and data system (PI-RADS) category 3 lesions. Methods: A retrospective analysis was conducted on lesions diagnosed as PI-RADS 3. They were categorized into benign, non-csPCa and csPCa groups. Apparent diffusion coefficient (ADC), T2-weighted imaging signal intensity (T2WISI), coefficient of variation of ADC and T2WISI, prostate-specific antigen density (PSAD), ADC density (ADCD), prostate-specific antigen lesion volume density (PSAVD) and ADC lesion volume density (ADCVD) were measured and calculated. Univariate and multivariate analyses were used to identify risk factors associated with PCa and csPCa. Receiver operating characteristic curve (ROC) and decision curves were utilized to assess the efficacy and net benefit of independent risk factors. Results: Among 202 patients, 133 had benign prostate disease, 25 non-csPCa and 44 csPCa. Age, PSA and lesion location showed no significant differences (P> 0.05) among the groups. T2WISI and coefficient of variation of ADC (ADCcv) were independent risk factors for PCa in PI-RADS 3 lesions, yielding an area under the curve (AUC) of 0.68. ADC was an independent risk factor for csPCa in PI-RADS 3 lesions, yielding an AUC of 0.65. Decision curve analysis showed net benefit for patients at certain probability thresholds. Conclusions: T2WISI and ADCcv, along with ADC, respectively showed considerable promise in enhancing the diagnosis of PCa and csPCa in PI-RADS 3lesions.
引用
收藏
页码:371e1 / 371e10
页数:10
相关论文
共 50 条
  • [21] Impact of PI-RADS Category 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: A systematic review and meta-analysis
    Wadera, Akshay
    Alabousi, Mostafa
    Pozdnyakov, Alex
    Al-Ghita, Mohammed Kashif
    Jafri, Ali
    McInnes, Matthew D. F.
    Schieda, Nicola
    van der Pol, Christian B.
    Salameh, Jean-Paul
    Samoilov, Lucy
    Gusenbauer, Kaela
    Alabousi, Abdullah
    BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1118):
  • [22] Clinical and Radiological Factors for Predicting Clinically Significant Prostate Cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions
    Zhang, Zhiyu
    Hu, Can
    Lin, Yuxin
    Song, Ouyang
    Gong, Dongkui
    Zhang, Xuefeng
    Wang, Nan
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [23] MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?
    Schoots, Ivo G.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2018, 7 (01) : 70 - +
  • [24] Re: PI-RADS 3 Lesions: Role of Prostate MRI Texture Analysis in the Identification of Prostate Cancer Editorial Comment
    Siegel, Cary
    JOURNAL OF UROLOGY, 2022, 207 (05): : 1132 - 1132
  • [25] Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer
    Thai, Janice N.
    Narayanan, Harish A.
    George, Arvin K.
    Siddiqui, M. Minhaj
    Shah, Parita
    Mertan, Francesca V.
    Merino, Maria J.
    Pinto, Peter A.
    Choyke, Peter L.
    Wood, Bradford J.
    Turkbey, Baris
    RADIOLOGY, 2018, 288 (02) : 485 - 491
  • [26] Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to previous PI-RADS versions
    Bogner, Katja
    Engelhard, Karl
    Wuest, Wolfgang
    Hamel, Sajad
    ABDOMINAL RADIOLOGY, 2022, 47 (06) : 2187 - 2196
  • [27] Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to previous PI-RADS versions
    Katja Bogner
    Karl Engelhard
    Wolfgang Wuest
    Sajad Hamel
    Abdominal Radiology, 2022, 47 : 2187 - 2196
  • [28] Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancer
    Nayana U. Patel
    Kimberly E. Lind
    Kavita Garg
    David Crawford
    Priya N. Werahera
    Sajal S. Pokharel
    Abdominal Radiology, 2019, 44 : 705 - 712
  • [29] Perilesional Biopsies Increase Detection of Significant Prostate Cancer in Men with PI-RADS 4/5 Lesions: Validation of the PI-RADS Steering Committee Recommendation
    Lahoud, John
    Doan, Paul
    Kim, Lawrence
    Patel, Manish I.
    EUROPEAN UROLOGY, 2021, 80 (02) : 260 - 261
  • [30] PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer?
    Rico, Luis
    Blas, Leandro
    Vitagliano, Gonzalo
    Contreras, Pablo
    Pita, Hernando Rios
    Ameri, Carlos
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (07) : 431.e9 - 431.e13